These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Clara JA; Monge C; Yang Y; Takebe N Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354 [TBL] [Abstract][Full Text] [Related]
32. The challenge of targeting metastasis. Fidler IJ; Kripke ML Cancer Metastasis Rev; 2015 Dec; 34(4):635-41. PubMed ID: 26328524 [TBL] [Abstract][Full Text] [Related]
33. Metastasis-directed therapy for oligometastasis and beyond. Beckham TH; Yang TJ; Gomez D; Tsai CJ Br J Cancer; 2021 Jan; 124(1):136-141. PubMed ID: 33204024 [TBL] [Abstract][Full Text] [Related]
34. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Wong MS; Sidik SM; Mahmud R; Stanslas J Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409 [TBL] [Abstract][Full Text] [Related]
35. Cadherins as novel targets for anti-cancer therapy. Blaschuk OW; Devemy E Eur J Pharmacol; 2009 Dec; 625(1-3):195-8. PubMed ID: 19836380 [TBL] [Abstract][Full Text] [Related]
36. Autophagy : Moving Benchside Promises to Patient Bedsides. Belaid A; Ndiaye PD; Filippakis H; Roux J; Röttinger É; Graba Y; Brest P; Hofman P; Mograbi B Curr Cancer Drug Targets; 2015; 15(8):684-702. PubMed ID: 26452384 [TBL] [Abstract][Full Text] [Related]
37. Current treatment of metastatic endometrial cancer. Temkin SM; Fleming G Cancer Control; 2009 Jan; 16(1):38-45. PubMed ID: 19078928 [TBL] [Abstract][Full Text] [Related]
38. Cancer metastasis: a search for therapeutic inhibition. Dimitroff CJ; Sharma A; Bernacki RJ Cancer Invest; 1998; 16(4):279-90. PubMed ID: 9589037 [TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. Lin Y; Xu J; Lan H J Hematol Oncol; 2019 Jul; 12(1):76. PubMed ID: 31300030 [TBL] [Abstract][Full Text] [Related]
40. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Mahal K; Kahlen P; Biersack B; Schobert R Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]